Fetal Nigral Cell Transplants for Parkinson’s — the Brain Graft That Triggered Unswitchable Dyskinesias

In 1987 a team led by neurologist Olle Lindvall and neuroscientist Anders Björklund at Lund University, Sweden, began implanting dopamine-producing cells dissected from aborted human fetuses into the brains of Parkinson’s patients; the open-label results of the 1990s — surviving grafts on PET, patients walking who had been frozen — were celebrated as the first biological cure for a neurodegenerative disease. The gap between that promise and the controlled evidence is the case. Tested the way a drug would be — against sham brain surgery, double-blind — the graft did not beat placebo on its primary endpoint and inflicted a new, largely untreatable harm: persistent involuntary movements that ran on after every drop of levodopa was withdrawn.

Both trials that ended the era were funded by the U.S. National Institutes of Health and built around a placebo arm earlier enthusiasts had called unnecessary. In Curt Freed’s Denver–Columbia trial, published in The New England Journal of Medicine on March 8, 2001, 40 patients aged 34 to 75 were randomized to a fetal-tissue graft or to sham surgery — burr holes drilled, no cells implanted. The graft showed no benefit on the pre-specified global rating; a positive signal appeared only in a post-hoc subgroup aged 60 or younger. Then came the harm: dystonia and dyskinesias in roughly 15 percent of grafted patients (5 of 33), persisting after levodopa was reduced or stopped. The second NIH trial, run by neurologist C. Warren Olanow and published in Annals of Neurology in September 2003, deepened the failure: across 34 patients, no significant effect on the motor UPDRS (p = 0.244) at 24 months, 56 percent with off-medication dyskinesia, and a conclusion that transplantation “currently cannot be recommended as a therapy.”

The case is exemplary because the grafts worked biologically and failed clinically. Fluorodopa uptake rose; dopamine neurons survived robustly and were confirmed at autopsy. The cells lived — but thriving grafts drove a runaway, unregulated release of dopamine the brain could not modulate, leaving a procedure that could not be titrated, withdrawn, or reversed: a worse failure mode than the disease it meant to cure. The field abandoned routine fetal grafting and turned to the problem it had skipped — proving, against placebo, that putting cells in a brain helps the person attached to it.